COLOGNE, Germany—Gene-transfer specialist amaxa and Lafayette, Colo.-based Dharmacon, a division of Fisher Biosciences, recently announced an agreement to co-promote Dharmacon's siRNA libraries with the German company's Nucleofactor technology.
The hope is that the combined technologies will further facilitate the application of RNAi-based gene silencing in drug discovery and development by improving the high-throughput transfer of nucleic acids into cells.
According to Dr. William Marshall, VP of technology and business development at Fisher Biosciences, the two companies will work closely to provide customers with coordinated technical service, pre-tested protocols, and application models.
"We believe Dharmacon provides excellent quality siRNA, and that made the company an obvious choice for partnering," Rainer Christine, CEO of amaxa, added. "By working closely with Dharmacon, we can help researchers accelerate the speed and accuracy of their experiments using siRNA."
